Subramanyam Chittivelu

Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial

Harry Heijerman, Edward F. McKone, D.G. Downey et al. · The Lancet · 2019 · 1.4K citations · Full text

Life Sciences, Genetics, Pharmacology +14

Inhibition of invasion, angiogenesis, tumor growth, and metastasis by adenovirus-mediated transfer of antisense uPAR and MMP-9 in non–small cell lung cancer cells

Jasti S. Rao, Christopher S. Gondi, Chandramu Chetty et al. · Molecular Cancer Therapeutics · 2005 · 152 citations · Full text

Medicine, Cancer Biology, Oncology +11

Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials

Nicole Mayer-Hamblett, Félix Ratjen, Renee Russell et al. · The Lancet Respiratory Medicine · 2022 · 126 citations · Full text

Pharmacy, Pharmacotherapy, Good Clinical Practice +8

Adenovirus-mediated small interfering RNA against matrix metalloproteinase-2 suppresses tumor growth and lung metastasis in mice

Chandramu Chetty, Praveen Bhoopathi, Pushpa A. Joseph et al. · Molecular Cancer Therapeutics · 2006 · 78 citations · Full text

Medicine, Cancer Biology, Oncology +15

Suppression of tumor cell invasiveness and in vivo tumor growth by microRNA-874 in non-small cell lung cancer

Divya Kesanakurti, Dilip Rajasekhar Maddirela, Subramanyam Chittivelu et al. · Biochemical and Biophysical Research Communications · 2013 · 52 citations · Full text

Medicine, Molecular Biology, Oncology +16